en · de · es · fr · pt
thymosin-alpha-1-notes.peptides4800.com › Info › Background, Structure, And Mechanism — Questions and Answers

Background, Structure, And Mechanism — Questions and Answers

By Editorial Desk · published 2026-02-10 · last reviewed 2026-03-18 · Info

The short version of 胸腺素α1 fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-03-18 and is reviewed periodically as new material appears.

Background, Structure, and Mechanism

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.

Molecular Background and Immune Action

Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.

Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.

Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Chemical classPeptide28 amino acid residues
Molecular weightApproximately 3108 DaDepends on acetylation state
N-terminal modificationAcetylatedAffects charge and stability
Natural sourceFragment of thymosin beta-4Cleaved in vivo
Sequence length28 residuesSynthetic form matches natural

Background and Molecular Profile

The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.

The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.

Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.

Related pages on this site

分子身份与天然来源

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

Molecular Structure and Biological Background

The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Supporting material

== History == Developed and proposed for the first time in England by Stephen Lewis and Ken Heaton at the University Department of Medicine, Bristol Royal Infirmary, it was suggested by the authors as a clinical assessment tool in 1997 in the Scandinavian Journal of Gastroenterology after a previous prospective study, conducted in 1992 on a sample of the population (838 men and 1,059 women), had shown an unexpected prevalence of defecation disorders related to the shape and type of stool. The authors of the former paper concluded that the form of the stool is a useful surrogate measure of colon transit time. That conclusion has since been challenged as having limited validity for Types 1 and 2; however, it remains in use as a research tool to evaluate the effectiveness of treatments for various diseases of the bowel, as well as a clinical communication aid.

== Organisational structure == The NNPC's business operations are managed through Strategic Business and Corporate Services Units (SBUs/CSUs) in diverse locations across Nigeria. The NNPC Group comprises the NNPC Board, the group managing director's office, Five directorates as listed below. Each of the directorate is headed by an executive vice president (EVP). Its divisions are headed by chiefs, while its subsidiary companies are headed by managing directors. NNPC has several subsidiaries, two partly owned subsidiaries and 16 associated companies. Directorates:

== Personal life and death == Concert dates in support of Sheik's 2011 album Covers 80s were canceled when Sheik sought treatment for alcoholism. In a message to fans on his Tumblr blog, Sheik noted that he had entered a treatment center on the same day his latest album was released and had told his staff, "My record is coming out and I'm checking in." Sheik had a daughter with his wife Nora Ariffin, an actress turned realtor. He practiced Nichiren Buddhism and was a member of the U.S. branch of the worldwide Buddhist association Soka Gakkai International. On September 16, 2026, Sheik was reported by his family on his Instagram page to be hospitalized in "critical but stable condition". He died the following day from heart and organ failure leading to cardiac arrest in New York City, at the age of 56.

The δDs of hydroxyl-bearing minerals of the mantle were estimated at −80‰ ~ −40‰ via analysis of the isotopic composition for juvenile water. Hydrogen minerals generally have large isotope effects, and the isotopic composition often follows the pattern observed for precipitation.

An urgent issue that had to be addressed was the economic crisis that began in 1974. Minister of Economy Fuentes Quintana proposed the signing of a great "social pact" that would "compensate" the harsh adjustment measures that had to be taken through social improvements and some juridical-political reforms. This led to the Moncloa Pacts signed on October 27, 1977, which succeeded in stabilizing the economy and controlling inflation ─ from 26.4% in 1977 to 16.5 the following year ─ and social spending was increased in return ─ unemployment benefits, pensions, education and health spending ─ thanks to the tax reform implemented by Minister Francisco Fernández Ordóñez. Another pressing matter was the "regional question", since the demands for self-government on the part of Catalonia and the Basque Country did not admit any further delay. In the case of Catalonia, the restoration of the Statute of Autonomy approved by the Republic was demanded, but Suárez opted to approve a decree-law of September 29, 1977, which "provisionally" restored the Generalitat although without reference to the 1932 Statute which allowed the return from exile of the "president" Josep Tarradellas. For the Basque Country, the Basque General Council was constituted in December 1977 under the presidency of the socialist Ramón Rubial, but as in the case of Catalonia, the Statute of Autonomy approved by the Republic was not reestablished either.

Sources: en.wikipedia.org

Supporting material

=== Designation process === The NIH funds cancer centers through a P30 Cancer Center Support Grant (CCSG) mechanism. To be eligible to apply, a cancer center must receive at least $10 million in cancer research funding annually. Preparation for these grant applications can be extensive. The most recent grant application prepared by MD Anderson Cancer Center took 24 months to prepare and ran to 2,963 pages. Cancer centers must renew their status with the NIH every 5 years. The NCI considers the certain characteristics essential to a cancer center, and requires that applications address the institutions' resources in the areas of: Physical Space, Organizational Capabilities, Transdisciplinary Collaboration and Coordination, Cancer Focus, Institutional Commitment, Center Director. Independent or freestanding cancer centers are entities unto themselves and are not considered to be part of a larger institution or university. The center’s administration controls all space, appointments and budgets. These institutions may have university affiliations, but they remain administratively and financially distinct. The NCI also supports Consortium Centers, wherein scientists and clinicians from multiple institutions enter into formal agreements to expand cancer research programs. Importantly, Consortium Partners are not themselves considered NCI-designated. The NCI has strict guidelines on how Consortium Partners can refer to their relationship with their parent Consortium Center.

== See also == Analysis, the converse of synthesis Carlson curve Synthesizer (disambiguation) Synthetic (disambiguation) Creation (disambiguation) Formation (disambiguation) Production (disambiguation) Derivation (disambiguation)

Legal opium production is allowed under the United Nations Single Convention on Narcotic Drugs and other international drug treaties, subject to strict supervision by the law enforcement agencies of individual countries. The leading legal production method is the Robertson-Gregory process, whereby the entire poppy, excluding roots and leaves, is mashed and stewed in dilute acid solutions. The alkaloids are then recovered via acid-base extraction and purified. The exact date of its discovery is unknown, but it was described by Wurtz in his Dictionnaire de chimie pure et appliquée published in 1868. Legal opium production in India is much more traditional. As of 2008, opium was collected by farmers who were licensed to grow 0.1 hectares (0.25 acres) of opium poppies, who to maintain their licences needed to sell 56 kilograms of unadulterated raw opium paste. The price of opium paste is fixed by the government according to the quality and quantity tendered. The average is around 1500 rupees (US$29) per kilogram. Some additional money is made by drying the poppy heads and collecting poppy seeds, and a small fraction of opium beyond the quota is sometimes consumed locally or diverted to the black market. The opium paste is dried and processed into government opium and alkaloid factories before it is packed into cases of 60 kilograms for export. Purification of chemical constituents is done in India for domestic production, but typically done abroad by foreign importers.

== Medical uses == Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. In May 2022, the US Food and Drug Administration (FDA) expanded the indication to include the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. In August 2022, the FDA expanded the indication to include the treatment of unresectable or metastatic HER2-low breast cancer. In April 2024, the FDA expanded the indication to include the treatment of unresectable or metastatic HER2-positive (IHC3+) solid tumors for adults who have received prior systemic treatment and have no satisfactory alternative treatment options.

Sources: en.wikipedia.org

Supporting material

The effectiveness of light therapy for treating seasonal affective disorder (SAD) may be linked to reduced sunlight exposure in the winter months. Light resets the body's internal clock. Studies show that light therapy helps reduce the debilitating depressive symptoms of SAD, such as excessive sleepiness and fatigue, with results lasting for at least 1 month. Light therapy is preferred over antidepressants in the treatment of SAD because it is a relatively safe and easy therapy with minimal side effects. Two methods of light therapy, bright light and dawn simulation, have similar success rates in the treatment of SAD. It is possible that response to light therapy for SAD could be season dependent. Morning therapy has provided the best results because light in the early morning aids in regulating the circadian rhythm. People affected by SAD often have low energy, tend to eat more carbohydrates and sleep longer, but symptoms can vary between people. A Cochrane review conducted in 2019 states the evidence that light therapy's effectiveness as a treatment for the prevention of seasonal affective disorder is limited, although the risk of adverse effects are minimal. Therefore, the decision to use light therapy should be based on a person's preference of treatment.

=== Reaction to Harry Potter partnership === In August 2026, Tim Horton announced its “Back to Hogwarts with Harry Potter” campaign, with a series of themed products released to mark the 25th anniversary of the release of the first film of the Harry Potter movie franchise. The campaign received criticism from the 2SLGBTQ+ community, with Tim Horton being rebranded by online activists as "TERF-Hortons" for being perceived to be aligning themselves with J.K. Rowling's "anti-trans" views. Advocacy group Egale Canada argued that "as a brand that is synonymous with Canada, Tim Hortons and their partnerships should reflect Canada — a country that is inclusive and proud of its diversity".

In December 2024, Trump stated a further proposal for the United States to purchase Greenland from Denmark, describing "ownership" and control of the island as "an absolute necessity" for national security purposes. This builds upon a prior offer from Trump to buy Greenland during his first term, which the Danish Realm refused, causing him to cancel his August 2019 visit to Denmark. On January 7, 2025, Trump's son Donald Trump Jr. visited Greenland's capital city Nuuk alongside Charlie Kirk to hand out MAGA hats. At a press conference the following day, Trump refused to rule out military or economic force to take over Greenland or the Panama Canal. However, he did rule out military force in taking over Canada. On January 14, the Trump-affiliated Nelk Boys also visited Nuuk, handing out dollar bills to locals. On January 16, the CEOs of major Danish companies Novo Nordisk, Vestas and Carlsberg among others were assembled for a crisis meeting in the Ministry of State to discuss the situation. On the subsequent day, former chief executive Friis Arne Petersen in the Danish Ministry of Foreign Affairs described the situation as "historically unheard of", while Noa Redington, special adviser to former prime minister Helle Thorning-Schmidt, compared the international pressure on Denmark that during the 2005 Jyllands-Posten Muhammad cartoons controversy. On February 12, 2025, a bill was introduced in Congress to advance efforts to acquire Greenland and rename it Red, White, and Blueland.

In 2010, Medpace acquired the Minneapolis medical-device consultancy Symbios and Germany's Medical Consulting Dr. Schlichtiger GmbH. In 2012 they acquired MediTech BV, a medical device consultancy based in the Netherlands.

Other powerful extensions to the dead-end elimination algorithm include the pairs elimination criterion, and the generalized dead-end elimination criterion. This algorithm has also been extended to handle continuous rotamers with provable guarantees. Although the Dead-end elimination algorithm runs in polynomial time on each iteration, it cannot guarantee convergence. If, after a certain number of iterations, the dead-end elimination algorithm does not prune any more rotamers, then either rotamers have to be merged or another search algorithm must be used to search the remaining search space. In such cases, the dead-end elimination acts as a pre-filtering algorithm to reduce the search space, while other algorithms, such as A*, Monte Carlo, Linear Programming, or FASTER are used to search the remaining search space.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha-1 derived from?

It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.

Is thymosin alpha-1 classified as a hormone?

It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.

How well established is its mechanism of action?

The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.

What is thymosin alpha 1 made of?

It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.

Network